Eiger BioPharmaceuticals (EIGR) Upgraded by Zacks Investment Research to Hold

Eiger BioPharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Eiger BioPharmaceuticals Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Eiger BioPharmaceuticals (EIGR) Upgraded by Zacks Investment Research to Hold

thoughts on these estimates, before EPS results? NASDAQ:KDMN, NASDAQ:EIGR, NASDAQ:SLRX, NASDAQ:FGBI

Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis…

View More thoughts on these estimates, before EPS results? NASDAQ:KDMN, NASDAQ:EIGR, NASDAQ:SLRX, NASDAQ:FGBI